[Ad hoc announcement pursuant to Art. 53 LR] Roche gives replace on section II/III SKYSCRAPER-06 research in metastatic non-squamous non-small cell lung most cancers

• SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy didn’t meet the first endpoints of progression-free survival at major evaluation and total survival at first interim evaluation

• The mixture of tiragolumab plus Tecentriq and chemotherapy confirmed decreased efficacy in comparison with the comparator arm

• Security was per earlier research, nevertheless we intend to halt the trial attributable to decreased efficacy in comparison with the comparator arm

Basel, 04 July 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) introduced at this time that the section II/III SKYSCRAPER-06 research, evaluating tiragolumab plus Tecentriq^® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an preliminary (first-line) therapy for folks with beforehand untreated, regionally superior unresectable or metastatic non-squamous non-small cell lung most cancers, didn’t meet its major endpoints of progression-free survival (PFS) at its major evaluation with a hazard ratio (HR) of 1.27 [95% CI: 1.02,1.57] and total survival (OS) at its first interim evaluation with a HR of 1.33 [95% CI: 1.02, 1.73], which was immature. The mixture of tiragolumab plus Tecentriq and chemotherapy confirmed decreased efficacy in each PFS and OS in comparison with the comparator arm within the intent-to-treat inhabitants, which incorporates the section II and section III cohorts. The general security profile stays per the protection profile beforehand noticed for the mixture of tiragolumab plus Tecentriq and chemotherapy, and no new or surprising findings had been recognized. Based mostly on these outcomes, sufferers and investigators shall be unblinded and we intend to halt the research. A communication shall be despatched to the investigators and outcomes shall be shared with well being authorities and subsequently introduced at an upcoming medical assembly.

“These outcomes are disappointing because it was our hope that this mix may yield improved outcomes for folks residing with metastatic non-squamous lung most cancers,” stated Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of World Product Improvement. “We’re grateful to all the sufferers and healthcare professionals concerned within the research, and we’ll leverage the learnings to tell our scientific understanding of the anti-TIGIT pathway and new avenues in most cancers analysis.”

Ongoing section III research are investigating therapy settings and indications distinct from SKYSCRAPER-06. Based mostly on at this time’s outcomes, we’ll consider any related modifications wanted to the continuing tiragolumab programme.

About SKYSCRAPER-06 research
SKYSCRAPER-06 is a worldwide section II/III, randomised, placebo-controlled and double-blinded research evaluating tiragolumab plus Tecentriq^® (atezolizumab) and chemotherapy as an preliminary (first-line) therapy versus pembrolizumab and chemotherapy in 542 folks with non-squamous non- small cell lung most cancers. Major endpoints are total survival (OS) and progression-free survival (PFS).

Story continues

About tiragolumab
Tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc area. Tiragolumab selectively binds to TIGIT, a novel inhibitory immune checkpoint which suppresses the immune response to most cancers. Based mostly on preclinical analysis, tiragolumab is assumed to work as an immune amplifier with different most cancers immunotherapies reminiscent of Tecentriq® (atezolizumab). The TIGIT pathway is distinct however complementary to the PD-L1/PD-1 pathway. Twin blockade with tiragolumab and Tecentriq might assist overcome immune suppression and restore the immune response.

About Tecentriq^® (atezolizumab)
Tecentriq is a most cancers immunotherapy authorised for among the most aggressive and difficult-to-treat types of most cancers. Tecentriq was the primary most cancers immunotherapy authorised for the therapy of a sure kind of early-stage (adjuvant) non-small cell lung most cancers (NSCLC), small cell lung most cancers (SCLC) and hepatocellular carcinoma (HCC). Tecentriq can be authorised in international locations around the globe, both alone or together with focused therapies and/or chemotherapies, for numerous types of metastatic NSCLC, sure forms of metastatic urothelial most cancers (mUC), PD-L1-positive metastatic triple-negative breast most cancers (TNBC), BRAF V600 mutation-positive superior melanoma and alveolar tender half sarcoma (ASPS).

Tecentriq is a monoclonal antibody designed to bind with a protein known as programmed loss of life ligand-1 (PD-L1), which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with each PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq might allow the activation of T-cells. Tecentriq is a most cancers immunotherapy that has the potential for use as a foundational mixture companion with different immunotherapies, focused therapies and numerous chemotherapies throughout a broad vary of cancers.

Along with intravenous infusion, Tecentriq has been authorised as a subcutaneous formulation in over 40 international locations. The authorised indications for Tecentriq SC mirror these of Tecentriq IV.

About Roche
Based in 1896 in Basel, Switzerland, as one of many first industrial producers of branded medicines, Roche has grown into the world’s largest biotechnology firm and the worldwide chief in in-vitro diagnostics. The corporate pursues scientific excellence to find and develop medicines and diagnostics for enhancing and saving the lives of individuals around the globe. We’re a pioneer in personalised healthcare and wish to additional remodel how healthcare is delivered to have a good larger affect. To offer the very best take care of every individual we companion with many stakeholders and mix our strengths in Diagnostics and Pharma with information insights from the medical follow.

In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the vital sustainable firms within the prescription drugs business by the Dow Jones Sustainability Indices for the fifteenth consecutive yr. This distinction additionally displays our efforts to enhance entry to healthcare along with native companions in each nation we work.

Genentech, in america, is a completely owned member of the Roche Group. Roche is almost all shareholder in Chugai Pharmaceutical, Japan.

For extra info, please go to www.roche.com.

All emblems used or talked about on this launch are protected by legislation.

Roche World Media Relations

Cellphone: +41 61 688 8888 / e-mail: media.relations@roche.com

Roche Investor Relations

Investor Relations North America

Attachment